Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma
A Elmusrati, J Wang, CY Wang - International journal of oral science, 2021 - nature.com
Head and neck squamous cell carcinoma (HNSCC), an aggressive malignancy, is
characterized by high morbidity and low survival rates with limited therapeutic options …
characterized by high morbidity and low survival rates with limited therapeutic options …
[HTML][HTML] Essentials of oral cancer
C Rivera - International journal of clinical and experimental …, 2015 - ncbi.nlm.nih.gov
Oral cancer is one of the 10 most common cancers in the world, with a delayed clinical
detection, poor prognosis, without specific biomarkers for the disease and expensive …
detection, poor prognosis, without specific biomarkers for the disease and expensive …
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
EEW Cohen, RB Bell, CB Bifulco, B Burtness… - … for immunotherapy of …, 2019 - Springer
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy
M Canning, G Guo, M Yu, C Myint… - Frontiers in cell and …, 2019 - frontiersin.org
Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …
[HTML][HTML] Mining TCGA database for genes of prognostic value in glioblastoma microenvironment
Glioblastoma (GBM) is one of the most deadly brain tumors. The convenient access to The
Cancer Genome Atlas (TCGA) database allows for large-scale global gene expression …
Cancer Genome Atlas (TCGA) database allows for large-scale global gene expression …
The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
EJ de Ruiter, ML Ooft, LA Devriese… - Oncoimmunology, 2017 - Taylor & Francis
Background–The presence of tumor-infiltrating lymphocytes (TILs) in the tumor
microenvironment is associated with an improved prognosis and a better response to …
microenvironment is associated with an improved prognosis and a better response to …
[HTML][HTML] Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature
EI Deryugina, JP Quigley - Matrix Biology, 2015 - Elsevier
Metastasis is a distinct stage of cancer progression that requires the development of
angiogenic blood vessels serving as conduits for tumor cell dissemination. An accumulated …
angiogenic blood vessels serving as conduits for tumor cell dissemination. An accumulated …
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
H Zaryouh, M Vara-Messler, J Vignau… - Drug Resistance …, 2022 - Elsevier
Squamous cell carcinoma of the head and neck (SCCHN) is among the most prevalent
cancer types worldwide. Despite multimodal therapeutic approaches that include surgical …
cancer types worldwide. Despite multimodal therapeutic approaches that include surgical …
Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
Head and neck squamous cell carcinoma (HNSCC) is a very aggressive disease with a poor
prognosis for advanced-stage tumors. Recent clinical, genomic, and cellular studies have …
prognosis for advanced-stage tumors. Recent clinical, genomic, and cellular studies have …
Anti–PD-1 and anti–PD-L1 in head and neck cancer: a network meta-analysis
A Botticelli, A Cirillo, L Strigari, F Valentini… - Frontiers in …, 2021 - frontiersin.org
Objective The monoclonal antibodies anti-programmed death protein-1 (anti–PD-1)
nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for …
nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for …